NR4A1 and breast carcinoma: For instance, a randomized clinical trial in hormone receptor-positive, HER2-negative metastatic breast cancer patients did not observe significant differences in median PFS or ORR when Eribulin was combined with pembrolizumab compared to Eribulin monotherapy (50).